Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Breast Neoplasms 41Melanoma 8Uterine Cervical Neoplasms 7Endometrial Neoplasms 7Mouth Neoplasms 4Carcinoma, Intraductal, Noninfiltrating 4Vulvar Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Uterine Neoplasms 2Rectal Neoplasms 2Neoplasm Micrometastasis 2Neoplasm Metastasis 2Lymphatic Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Eccrine Porocarcinoma 2Breast Neoplasms, Male 2Breast Carcinoma In Situ 2Waldenstrom Macroglobulinemia 1Sentinel Lymph Node Biopsy (SLNB) 1Sentinel Lymph Node 1Sarcoidosis, Pulmonary 1Sarcoidosis 1Recurrence 1Recurent Vulvar Carcinoma 1Prostatic Neoplasms 1Penile Neoplasms 1Pediatric Patients With Solid Tumors 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 220Rituximab 189fludarabine phosphate 169fludarabine 102Peripheral Blood Stem Cell Transplantation 100Mycophenolic Acid 94Whole-Body Irradiation 81Tacrolimus 72Filgrastim 69Cyclosporine 67Lenalidomide 66ibrutinib 63Busulfan 61Melphalan 58Antilymphocyte Serum 57Radiotherapy 52venetoclax 48Etoposide 47obinutuzumab 42Bendamustine Hydrochloride 42Alemtuzumab 41Methotrexate 39ofatumumab 28sargramostim 27Granulocyte Colony-Stimulating Factor 26Cytarabine 26Cord Blood Stem Cell Transplantation 26acalabrutinib 25Stem Cell Transplantation 24Specimen Handling 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × Sentinel Lymph Node Biopsy × Clear all
NCT01649791 2016-06-30

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Roswell Park Cancer Institute

Phase NA Terminated
8 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00621452 2014-08-06

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡